[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2008/1101,2008,A2Locationinpatent:Page/Pagecolumn360-361
[2]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2007/129062,2007,A1Locationinpatent:Page/Pagecolumn196-197
[3]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-US2010/21420,2010,A1
[4]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2008/9954,2008,A1Locationinpatent:Page/Pagecolumn102-103
[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2006/77414,2006,A1Locationinpatent:Page/Pagecolumn157-158;175
[1]Patent:WO2006/77414,2006,A1.Locationinpatent:Page/Pagecolumn183
[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2006/77414,2006,A1Locationinpatent:Page/Pagecolumn169-170
[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2006/77414,2006,A1Locationinpatent:Page/Pagecolumn167-168
Title: Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.
Journal: Journal of medicinal chemistry 20080828
Title: Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36.
Title: Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Title: Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8.
